Abstracts tagged "Infection"

Abstract Number: 0486 • ACR Convergence 2025
Safety of sarilumab in more than 1000 patients with rheumatoid arthritis in Japan by age group: a post-marketing surveillance study
Hideto Kameda¹, Sadatomo Tasaka², Toshiya Takahashi³, Naoki Soeda³, Katsuhisa Suzuki⁴ and Yoshiya Tanaka⁵, ¹Department of Internal Medicine, Toho University, Tokyo, Japan, ²Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan, ³Medical Affairs, Asahi Kasei Pharma Corporation, Tokyo, Japan, ⁴Medical Affairs, Sanofi K.K., Tokyo, Japan, ⁵University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: Sarilumab (SAR) is approved as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) for treatment of patients (pts) with moderate-to-severely active…
Abstract Number: 2505 • ACR Convergence 2025
Avacopan is Not Associated With An Increased Risk of Infection Compared to Glucocorticoids in Patients with ANCA-Associated Vasculitis
BEATRIZ MARIA FRANCO HONDERMANN, LOYOLA UNIVERSITY MEDICAL CENTER, OAK PARK
Background/Purpose: Avacopan is a novel C5a receptor inhibitor recently approved for treatment of ANCA-associated vasculitis as an alternative to glucocorticoids, It has demonstrated superior efficacy…
Abstract Number: 1304 • ACR Convergence 2025
The role of PET/CT in evaluating rheumatologic conditions in children with fever of unknown origin – a multicenter study
Neta Berlak¹, Lydia Christodoulou², Gil Amarilyo³, Oded Scheuerman⁴, Irit Tirosh⁵, Eyal Kristal⁶, Ester Forer⁷, Amit Carmi⁸, Alon Kalter⁹ and Yoel Levinsky¹⁰, ¹Schneider children's medical center of Israel, Tel Aviv, Israel, ²Tel Hashomer, Periatric rheumatology unit, Tel Aviv, Israel, ³Schneider Children's Medical Center of Israel, Kibbutz Maggal, Israel, ⁴schneider children's meidcal center of Israel, Petah tikva, Israel, ⁵Tel Aviv universty, Ramat Gan, Israel, ⁶Soroka medical center Beer Sheva, Beer Sheva, Israel, ⁷Soroka medical center, Beer Sheva, Israel, ⁸Schneider children's meidcal center of Israel, Tel Aviv, Israel, ⁹Schneider children's medical center of ISrael, Petah Tikva, Israel, ¹⁰Schneider Children's Medical Cenetr of Israel, Tel Aviv University, JERUSALEM, Israel
Background/Purpose: Fever of Unknown Origin (FUO) is a relatively common clinical challenge that is frequently referred for evaluation by pediatric rheumatologists. In many cases, it…
Abstract Number: 0210 • ACR Convergence 2025
Improving Recombinant Zoster Vaccine Uptake in Younger Adults with Rheumatoid Arthritis through a Partnership with Specialty Pharmacy
Akhil Sood¹, Srijana Davuluri², Sheila Haidar³, De Suan Huang³, April Ochoa³, Christy Bill¹ and Janice Lin¹, ¹Stanford University, Palo Alto, CA, ²Stanford University, Stanford, CA, ³Stanford Health Care, Palo Alto, CA
Background/Purpose: Despite guideline recommendations, recombinant zoster vaccine (RZV) uptake remains low among immunocompromised individuals younger than 50 years of age, notably those with rheumatoid arthritis…
Abstract Number: 2292 • ACR Convergence 2025
Safety and Humoral Response to Recombinant Herpes Zoster Vaccine in immunosuppressed Sjögren’s Disease Patients: Results From a Double-Blinded Placebo-Controlled Study
Sandra G Pasoto¹, Talita Ribeiro², Nadia Emi Aikawa³, Ana C Medeiros-Ribeiro¹, Bruno Borges², Andre Franco⁴, Henrique Silva², Eloisa Bonfa⁵ and Clovis Artur Silva⁶, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ²Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, ³Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, São Paulo, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Sao Paulo, Brazil, ⁵Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ⁶University of São Paulo, São Paulo, São Paulo, Brazil
Background/Purpose: Immunosuppressed Sjögren’s disease (SjD) patients are at increased risk of herpes zoster (HZ). Despite this vulnerability, data on safety and immunogenicity of the recombinant…
Abstract Number: 1192 • ACR Convergence 2025
Idiopathic Inflammatory Myopathies: A Prospective Phase 4 Controlled Trial Of Recombinant Herpes Zoster Vaccine
Sandra G Pasoto¹, Thais B Gorayeb², Ana Paula Luppino-Assad³, Nadia E Aikawa⁴, Ana C Medeiros-Ribeiro¹, Leonard V Kupa⁵, Bruno S Borges⁶, Samuel K Shinjo⁷, Fernando H De Souza², Renata Miossi², Eloisa Bonfa⁸ and Clovis Artur Silva⁹, ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SAO PAULO, Brazil, ⁴Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Sao Paulo, Brazil, ⁶Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, ⁷Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, SÃO PAULO, Brazil, ⁸Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ⁹University of São Paulo, São Paulo, São Paulo, Brazil
Background/Purpose: Although herpes zoster vaccination has been evaluated in immunocompromised populations, studies assessing vaccine immunogenicity and safety in idiopathic inflammatory myopathies (IIM) are restricted to…
Abstract Number: 0208 • ACR Convergence 2025
Current practices and challenges in tuberculosis screening and preventive treatment among patients with rheumatic diseases: A multiregional physician survey in China
Xu Wang, Lifan Zhang and Lidan Zhao, Peking Union Medical College Hospital, Beijing, China (People's Republic)
Background/Purpose: This study aimed to assess the current clinical practices of tuberculosis (TB) infection screening and TB preventive treatment (TPT) among patients with rheumatic diseases,…
Abstract Number: 0238 • ACR Convergence 2024
Longitudinal Assessment of CD8+ T Cell Responses to SARS-CoV-2 Pre- and Post-breakthrough Infection and Its Association with COVID-19 Severity in Immunosuppressed Individuals
Aljawharah Alrubayyi¹, Aaron Shulkin¹, Judith James², Meggan Mackay³, Dinesh Khanna⁴, Amit Bar-Or⁵, Susan Macwana⁶, Ellen Goldmuntz⁷, James McNamara⁸, Sean McCarthy⁹, Matthew Sherman⁸, William Barry¹⁰, Ashley Pinckney¹¹, Sarah Walker¹⁰, Sara Tedeschi¹², Jeffrey Sparks¹³, Zachary Wallace¹⁴ and Gaurav Gaiha¹⁵, ¹Ragon Institute of Mass General, MIT and Harvard, Cambridge, MA, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Feinstein Institutes for Medical Research, Manhasset, NY, ⁴University of Michigan, Ann Arbor, MI, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Oklahoma Medical Research Foundation, Oklahoma City, ⁷NIAID/ NIH, Washington, DC, ⁸NIH, Bethesda, MD, ⁹DAIT/NIAID/NIH, Rockville, MD, ¹⁰Rho, Durham, NC, ¹¹Rho, St Louis Park, NC, ¹²Brigham and Women's Hospital, Boston, MA, ¹³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, ¹⁴Massachusetts General Hospital, Newton, MA, ¹⁵Massachusetts General Hospital, Boston, MA
Background/Purpose: Vaccines for SARS-CoV-2 have greatly reduced COVID-19 morbidity and mortality through the induction of neutralizing antibody responses. However, T cell responses are also induced…
Abstract Number: 0291 • ACR Convergence 2024
Safety of Biologic Therapy in Kidney Transplant Recipients with Inflammatory Diseases: Real-world Experience from a Tertiary Medical Center
Victoria Furer¹, Omer Kersh², Mark Berman³, Ayelet Grupper² and Ori Elkayam⁴, ¹Tel Aviv Medical Center, Tel Aviv, Israel, ²Tel Aviv Sourasky Medical Center, Tel Aviv, Tel Aviv, Israel, ³Tel Aviv Sourasky Medical Center, Kefar sava, Israel, ⁴Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
Background/Purpose: Management of solid-organ transplant (SOT) recipients with systemic inflammatory diseases represents a clinical challenge in the paucity of data related to the safety of…
Abstract Number: 1423 • ACR Convergence 2024
An Observational Analytical Study on HCV Patients with Sicca Manifestations Before and After Direct-Acting Antivirals in Comparison with Sjogren’s Disease; Infection versus Autoimmunity
Mohamed Tharwat Hegazy¹, Amina Maher², Tareq Algarf², Manar Abdul-Aziz², Osama Ashraf Wafa Mohamed³, Luca Quartuccio⁴, Naguib Zoheir², Salvatore De Vita⁵ and Gaafar Ragab⁶, ¹Faculty of Medicine, Cairo University, Cairo, Egypt, ²Cairo University, Cairo, Egypt, ³Newgiza University, Cairo, Egypt, ⁴Division of Rheumatology, Department of Medicine (DMED), University of Udine, Udine, Italy, Udine, Italy, ⁵Udine University, Udine, Italy, ⁶Cairo University, Egypt, Cairo, Egypt
Background/Purpose: Hepatitis C virus (HCV) is often associated with autoimmune features and extra-hepatic manifestations. Sicca symptoms are reported in about 30% of the cases. Both…
Abstract Number: 2611 • ACR Convergence 2024
Continuation versus Temporary Interruption of Immunomodulatory Agents in Case of an Infection in IRD Patients: Results of a Randomized Controlled Trial
Merel Opdam¹, Nathan den Broeder², Reinout van Crevel³, Lisa Schapink⁴, Léon Raijmakers⁴, Jasper Broen⁵, Lise Verhoef⁴ and Alfons den Broeder¹, ¹Sint Maartenskliniek, Ubbergen, Netherlands, ²Sint Maartenskliniek, Ubbergen, Gelderland, Netherlands, ³Radboudumc, Nijmegen, Netherlands, ⁴Sint Maartenskliniek, Nijmegen, Netherlands, ⁵Máxima Medical Centre, Eindhoven, Netherlands
Background/Purpose: Immunomodulatory agents (IA) are widely used for the treatment of inflammatory rheumatic diseases (IRDs). Although IA are safe and effective, management of infections and infection…
Abstract Number: 0240 • ACR Convergence 2024
Cellular and Humoral Responses Following a Fifth, Updated SARS-CoV-2 Vaccine Dose and Hybrid Immunity in Patients on TNF Inhibitors: A Prospective Cohort Study
Hilde S. Ørbo¹, Asia-Sophia Wolf², Taissa M. Kasahara³, Kristin H. Bjørlykke⁴, Ingrid Jyssum⁵, Joseph Sexton⁵, Anne Therese Tveter⁵, Guri Solum², Ingrid Fadum Kjønstad², Ingrid E. Christensen⁵, Tore K. Kvien⁶, Jørgen Jahnsen⁷, Espen A. Haavardsholm¹, Ludvig A. Munthe⁸, Sella A. Provan⁵, John Torgils Vaage⁸, Kristin K. Jørgensen⁴, Gunnveig Grødeland⁸, Siri Mjaaland², Silje W. Syversen⁹ and Guro L. Goll⁹, ¹Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ²Norwegian Institute of Public Health, Section for Immunology, Oslo, Norway, Oslo, Norway, ³University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ⁴Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway, ⁵Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ⁶Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ⁷Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, ⁸Oslo University Hospital, Department of Immunology, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ⁹Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Health and Society, Oslo, Norway, Oslo, Norway
Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapies have attenuated humoral vaccine responses and are prone to more severe infections. Assessing the persistence…
Abstract Number: 0304 • ACR Convergence 2024
Severe Infection in COVID-19 Vaccinated Patients with Systemic Autoimmune Rheumatic Diseases on B Cell Targeted Therapies: Association with Neutrophil-lymphocyte Ratio
doryan Garcia Olivas¹, Judith Hernández Sánchez¹, luis Bausá Gimeno¹, Javier Nóvoa Medina¹, Sergio Machín¹, Maria Ángeles Acosta-Mérida¹, Diana Botello-Corzo¹, daniel Batista Perdomo¹, José Ángel Hernández Beriain² and Beatriz Tejera Segura¹, ¹Rheumatology Department. Hospital Universitario Insular de Gran Canaria, las Palmas, Spain, ²Rheumatology Department. Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran C, Spain
Background/Purpose: Patients with systemic autoimmune rheumatic diseases (SARDs) are at higher risk of general infection due to the presence of comorbidities, underlying disease activity, and…
Abstract Number: 1483 • ACR Convergence 2024
Real World Data on Infections from the Indian SLE Inception Cohort for Research (INSPIRE): Spectrum and Risk Factors
SAUMYA TRIPATHY¹, DEBASISH PANDIT², Sarit Pattanaik³, Liza Rajasekhar⁴, VINEETA SHOBHA⁵, Chengappa Kavadichanda⁶, Ashish J Mathew⁷, Parasar Ghosh⁸, Ranjan Gupta⁹, Manish Rathi¹⁰, AVINASH JAIN¹¹, MANOJ PARIDA¹², Bidyut Das¹³ and Amita Aggarwal¹⁴, ¹SCB Medical College, Cuttack, Odisha, India, Cuttack, Orissa, India, ²SJM MCH, Puri, Puri, Orissa, India, ³SCB Medical College and Hospital, Cuttack, Odisha, Cuttack, Orissa, India, ⁴Nizam's Institute of Medical Sciences, Madhapur, Andhra Pradesh, India, ⁵ST JOHN'S MEDICAL COLLEGE, BENGALURU, Karnataka, India, ⁶Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India, ⁷Christian Medical College, Vellore, Tamil Nadu, India, ⁸Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, ⁹All India Institute of Medical Sciences, New Delhi, Delhi, India, ¹⁰Postgraduate Institute of Medical Education & Research, Chandigarh, Chandigarh, India, ¹¹SMS MCH, JAIPUR, JAIPUR, Rajasthan, India, ¹²SCB MEDICAL COLLEGE, CUTTACK, Cuttack, Orissa, India, ¹³SCB Medical College, Cuttack, Orissa, India, ¹⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Infections in SLE are a major cause of morbidity and mortality. The susceptibility to infections in SLE is multifactorial. Immune dysregulation, immunosuppressive drug use and…
Abstract Number: 2612 • ACR Convergence 2024
Two-Week Methotrexate Discontinuation in Autoimmune Rheumatic Diseases Patients Vaccinated with Recombinant Herpes Zoster Vaccine: An Interim Analysis of a Prospective Randomized Phase 4 Study
Ana Cristina Medeiros-Ribeiro¹, Joao de Oliveira², Nadia Aikawa³, Sandra Pasoto², Leonard Kupa², Carla Goncalves Schahin Saad⁴, Luciana Parente², ANA PAULA ASSAD², Eduardo Borba², Emily Figueiredo Neves Yuki², Andrea Shimabuco⁴, Karina Bonfiglioli², Diogo Domiciano², Percival Sampaio-Barros⁴, Andre Franco², Julio Moraes⁵, Murillo Dorio², Claudia Goldenstein-Schainberg², Henrique Carriço Da Silva², Lucas Guimarães², Fernanda Chaer⁶, Caio Laguna Reis de Carvalho², Henrique Dalmolin², Clovis Silva⁷ and Eloisa Bonfa², ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Jose Dos Campos, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ³Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Jundiai, Brazil, ⁶Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Santos, Brazil, ⁷Rheumatology Division and Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil
Background/Purpose: Temporary methotrexate (MTX) discontinuation may enhance vaccine immune response, but there are no data for the recombinant zoster vaccine (RZV). This study assessed if…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].